Arcadia Biosciences files S-8 as Nasdaq tests Arcadia Biosciences stock

Published on 10/16/2026 at 01:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The September 30 filing registered employee-plan shares. Nasdaq's USD 2.50 million equity test now frames Arcadia Biosciences stock.

Compliance and reporting dates

Arcadia Biosciences filed an employee-plan share registration on September 30, 2026.
Second-quarter 2026 revenue was USD 1.44 million and net loss was USD 6.27 million.
Third-quarter 2026 results are estimated for November 5, 2026, before market open.

RKDA, US0390143032, Illustration mit AI erstellt.

Arcadia Biosciences (US0390143032) filed an employee-plan share registration on September 30, 2026, while its Nasdaq listing position remained tied to a USD 2.50 million stockholders' equity threshold. The SEC filing identifies the registration as Form S-8.

Compliance is the central issue

According to Simply Wall St, Arcadia received a Nasdaq notice on August 31, 2026, because stockholders' equity stood at USD 633,000 on June 30, 2026, compared with the USD 2.50 million minimum. That gap is the key balance-sheet figure for the listing question.

Three filings mark the timeline

On August 13, 2026, Arcadia reported second-quarter revenue of USD 1.44 million and a net loss of USD 6.27 million. On August 31, 2026, the company received the Nasdaq equity notice tied to USD 633,000 of stockholders' equity. On September 30, 2026, Arcadia filed the S-8 registration, according to the SEC.

What happens on November 5?

MarketBeat estimates third-quarter 2026 results for November 5, 2026, before market open, with consensus revenue of USD 2.40 million and adjusted earnings per share of minus USD 0.46. The same page lists a conference call for November 12, 2026, at 4:00 p.m. ET.

Capital remains the constraint

The latest reported quarter ended June 30, 2026, with total assets of USD 5.89 million and cash of USD 4.18 million. Operating cash flow was negative USD 319,000 in that quarter, so the equity deficit relative to Nasdaq's threshold is more than a listing detail. It also shapes the company's financing choices and the significance of the September registration.

Business facts and risk

Arcadia develops plant-based wellness products and agricultural technologies, including GoodWheat, according to its investor-relations profile. The combination of a USD 633,000 equity balance, negative quarterly operating cash flow of USD 319,000 and the November reporting date gives the stock a clear compliance and funding test.